Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Preferred Stock Liabilities (2025)

Valion Bio has reported Preferred Stock Liabilities over the past 1 years, most recently at $6.0 million for Q4 2025.

  • For Q4 2025, Preferred Stock Liabilities changed N/A year-over-year to $6.0 million; the TTM value through Dec 2025 reached $6.0 million, changed N/A, while the annual FY2025 figure was $6.0 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2025 was $6.0 million at Valion Bio, up from $2.2 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $6.0 million in Q4 2025 and troughed at $2.2 million in Q3 2025.